The impact of metformin on progression-free survival of patients with advanced pancreatic well-differentiated neuroendocrinc tumor receiving everolimus plus somatostatin analog treatment

被引：1
|
作者：
Pusceddu, Sara
Buzzoni, Roberto
Giacomelli, Luca
Mazzaferro, Vincenzo
Concas, Laura
Mllione, Massimo
Formisano, Barbara
D'Autilla, Elise
Festinese, Fabrizio
De Braud, Filippo G.
机构：
[1] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[2] Natl Canc Inst, Milan, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.e15172
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15172
引用
收藏
页数：1
相关论文
共 50 条
  • [1] The impact of metformin on progression-free survival in patients with advanced pancreatic well differentiated neuroendocrine tumor receiving everolimus plus somatostatin analogue treatment
    Pusceddu, Sara
    Buzzoni, Roberto
    Concas, Laura
    Bregant, Cristina
    Leuzzi, Livia
    Milione, Massimo
    Seregni, Ettore
    Formisano, Barbara
    Consonni, Paola
    De Braud, Filippo
    CANCER RESEARCH, 2015, 75
  • [2] METFORMIN IMPACT ON PROGRESSION-FREE SURVIVAL IN ADVANCED PANCREATIC WELL-DIFFERENTIATED NEUROENDOCRINE TUMORS (PWDNETS). RETROSPECTIVE EVALUATION IN DIABETIC PATIENTS RECEIVING EVEROLIMUS PLUS OCTREOTIDE LAR TREATMENT
    Pusceddu, S.
    De Braud, F. G. M.
    Concas, L.
    Bregant, C.
    Festinese, F.
    Giacomelli, L.
    D'Autilia, E.
    Formisano, B.
    Mazzaferro, V.
    Buzzoni, R.
    ANNALS OF ONCOLOGY, 2014, 25
  • [3] Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study
    Carmona-Bayonas, Alberto
    Jimenez-Fonseca, Paula
    Lamarca, Angela
    Barriuso, Jorge
    Castano, Angel
    Benavent, Marta
    Alonso, Vicente
    Riesco-Martinez, Maria del Carmen
    Alonso-Gordoa, Teresa
    Custodio, Ana
    Sanchez Canovas, Manuel
    Hernando Cubero, Jorge
    Lopez, Carlos
    Lacasta, Adelaida
    Fernandez Montes, Ana
    Marazuela, Monica
    Crespo, Guillermo
    Escudero, Pilar
    Diaz, Jose Angel
    Feliciangeli, Eduardo
    Gallego, Javier
    Llanos, Marta
    Segura, Angel
    Vilardell, Felip
    Percovich, Juan Carlos
    Grande, Enrique
    Capdevila, Jaume
    Valle, Juan W.
    Garcia-Carbonero, Rocio
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (28) : 2571 - +
  • [4] Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues
    Pusceddu, Sara
    Vernieri, Claudio
    Di Maio, Massimo
    Marconcini, Riccardo
    Spada, Francesca
    Massironi, Sara
    Ibrahim, Toni
    Brizzi, Maria Pia
    Campana, Davide
    Faggiano, Antongiulio
    Giuffrida, Dario
    Rinzivillo, Maria
    Cingarlini, Sara
    Aroldi, Francesca
    Antonuzzo, Lorenzo
    Berardi, Rossana
    Catena, Laura
    De Divitiis, Chiara
    Ermacora, Paola
    Perfetti, Vittorio
    Fontana, Annalisa
    Razzore, Paola
    Carnaghi, Carlo
    Davi, Maria Vittoria
    Cauchi, Carolina
    Duro, Marilina
    Ricci, Sergio
    Fazio, Nicola
    Cavalcoli, Federica
    Bongiovanni, Alberto
    La Salvia, Anna
    Brighi, Nicole
    Colao, Annamaria
    Puliafito, Ivana
    Panzuto, Francesco
    Ortolani, Silvia
    Zaniboni, Alberto
    Di Costanzo, Francesco
    Torniai, Mariangela
    Bajetta, Emilio
    Tafuto, Salvatore
    Garattini, Silvio Ken
    Femia, Daniela
    Prinzi, Natalie
    Concas, Laura
    Lo Russo, Giuseppe
    Milione, Massimo
    Giacomelli, Luca
    Buzzoni, Roberto
    Delle Fave, Gianfranco
    GASTROENTEROLOGY, 2018, 155 (02) : 479 - +
  • [5] Everolimus in patients with advanced pancreatic neuroendocrine tumors (pNET): Impact of somatostatin analog use on progression-free survival in the RADIANT-3 trial
    Shah, M. H.
    Lombard-Bohas, C.
    Ito, T.
    Wolin, E. M.
    Van Cutsem, E.
    Sachs, C.
    Winkler, R. E.
    Lincy, J.
    Hobday, T. J.
    Yao, J. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] Metformin impact on progression-free survival in diabetic patients with advanced pancreatic neuroendocrine tumors (pNET) receiving everolimus and/or somatostatin analogues. The PRIME-NET (Pancreatic multicentric, Retrospective, Italian MEtformin) study
    Pusceddu, S.
    Marconcini, R.
    Spada, F.
    Massironi, S.
    Bongiovanni, A.
    Brizzi, M. P.
    Brighi, N.
    Colao, A.
    Giuffrida, D.
    Delle Fave, G.
    Cingarlini, S.
    Aroldi, F.
    Antonuzzo, L.
    Berardi, R.
    Catena, L.
    de Divitis, C.
    Ermacora, P.
    Di Maio, M.
    Buzzoni, R.
    de Braud, F.
    ANNALS OF ONCOLOGY, 2016, 27
  • [7] Metformin impact on progression-free survival in diabetic patients with advanced pancreatic neuroendocrine tumors (pNET) receiving everolimus and/or somatostatin analogues. The PRIME-NET (Pancreatic multicentric, Retrospective, Italian MEtformin) study
    Pusceddu, S.
    Marconcini, R.
    Spada, F.
    Cavalcoli, F.
    Ibrahim, T.
    Brizzi, M. P.
    Brighi, N.
    Faggiano, A.
    Puliafito, I.
    Delle Fave, G.
    Perfetti, V.
    Luppi, G.
    Carnaghi, C.
    Razzore, P.
    Davi, M. V.
    Cauchi, C.
    Duro, M.
    Di Maio, M.
    Buzzoni, R.
    Femia, D.
    De Braud, F.
    ANNALS OF ONCOLOGY, 2016, 27
  • [8] Impact of metformin on progression-free survival in diabetic patients with advanced pancreatic neuroendocrine tumors (pNETs) receiving everolimus and/or somatostatin analogues: A sensitivity analysis of the PRIME-NET (pancreatic multicentric, retrospective, italian metformin) study
    Pusceddu, Sara
    Vernieri, Claudio
    Di Maio, Massimo
    Daniela, Femia
    Prinzi, Natalie
    Marconcini, Riccardo
    Spada, Francesca
    Massironi, Sara
    Bongiovanni, Alberto
    Brizzi, Maria Pia
    Campana, Davide
    Faggiano, Antongiulio
    Giuffrida, Dario
    Delle Fave, Gianfranco
    Cingarlini, Sara
    Aroldi, Francesca
    Antonuzzo, Lorenzo
    Berardi, Rossana
    Catena, Laura
    Buzzoni, Roberto
    de Braud, Filippo
    CANCER RESEARCH, 2017, 77
  • [9] Visceral Obesity Is Associated with Shorter Progression-Free Survival in Well-Differentiated Gastro-Entero-Pancreatic Neuroendocrine Neoplasia
    Santos, Ana P.
    Rodrigues, Jessica
    Henrique, Rui
    Helena Cardoso, M.
    Monteiro, Mariana P.
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (20)
  • [10] Evaluation of progression-free survival by blinded independent central review in patients with progressive, well-differentiated pancreatic neuroendocrine tumors treated with sunitinib or placebo
    Van Cutsem, E.
    Seitz, J. F.
    Raoul, J.
    Valle, J. W.
    Faivre, S. J.
    Patyna, S.
    Klademenos, D.
    Lu, D.
    Chao, R. C.
    Raymond, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
12345